Long-Term Data Boost Novartis And Roche SMA Challenge To Biogen’s Spinraza
Rivals’ Revenues Could Overtake Spinraza In 2023
New long-term data from Novartis’s Zolgensma and Roche’s Erysdi will help close the gap on Biogen’s market leader Spinraza, but the three therapies look set to develop distinct or even complementary roles as the market matures.
